Low-Dose-Rate Prostate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavorable Risk Prostate Cancer: The Results of the ASCENDE-RT Randomized Control Trial
S. Rodda(University of British Columbia), William Morris(Vanderbilt University), Howard Pai(BC Cancer Agency), Jeremy Hamm, Michael McKenzie(Provincial Health Services Authority), Gillian Duncan(University of British Columbia), Scott Tyldesley(BC Cancer Agency), Mira Keyes(BC Cancer Agency)
International Journal of Radiation Oncology*Biology*Physics
October 17, 2015
Cited by 16
Related Papers
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319
cAMP regulates morphogenesis in the fungal pathogen Ustilago maydis.
|Genes & Development|1994|303